SK287806B6 - Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B) - Google Patents

Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B) Download PDF

Info

Publication number
SK287806B6
SK287806B6 SK1610-2003A SK16102003A SK287806B6 SK 287806 B6 SK287806 B6 SK 287806B6 SK 16102003 A SK16102003 A SK 16102003A SK 287806 B6 SK287806 B6 SK 287806B6
Authority
SK
Slovakia
Prior art keywords
methyl
amide
carboxylic acid
amino
indole
Prior art date
Application number
SK1610-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK16102003A3 (sk
Inventor
Peter Bernartino
Alan Elwood Blize
Brian Scott Bronk
Hengmiao Cheng
Hiep Huatan
Jin Li
Clive Philip Mason
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SK16102003A3 publication Critical patent/SK16102003A3/sk
Publication of SK287806B6 publication Critical patent/SK287806B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
SK1610-2003A 2001-06-28 2002-05-24 Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B) SK287806B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30164401P 2001-06-28 2001-06-28
PCT/IB2002/001876 WO2003002533A1 (en) 2001-06-28 2002-05-24 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion

Publications (2)

Publication Number Publication Date
SK16102003A3 SK16102003A3 (sk) 2004-08-03
SK287806B6 true SK287806B6 (sk) 2011-10-04

Family

ID=23164253

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1610-2003A SK287806B6 (sk) 2001-06-28 2002-05-24 Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)

Country Status (47)

Country Link
US (5) US6720351B2 (US06720351-20040413-C00013.png)
EP (1) EP1404653B1 (US06720351-20040413-C00013.png)
JP (1) JP4139325B2 (US06720351-20040413-C00013.png)
KR (2) KR100575944B1 (US06720351-20040413-C00013.png)
CN (2) CN1522246B (US06720351-20040413-C00013.png)
AP (1) AP1649A (US06720351-20040413-C00013.png)
AR (1) AR036158A1 (US06720351-20040413-C00013.png)
AT (1) ATE405548T1 (US06720351-20040413-C00013.png)
AU (1) AU2002307839B2 (US06720351-20040413-C00013.png)
BG (1) BG108487A (US06720351-20040413-C00013.png)
BR (1) BR0210616A (US06720351-20040413-C00013.png)
CA (1) CA2451474C (US06720351-20040413-C00013.png)
CR (1) CR7151A (US06720351-20040413-C00013.png)
CY (1) CY1108407T1 (US06720351-20040413-C00013.png)
CZ (1) CZ20033558A3 (US06720351-20040413-C00013.png)
DE (1) DE60228447D1 (US06720351-20040413-C00013.png)
DK (1) DK1404653T3 (US06720351-20040413-C00013.png)
EA (1) EA007008B1 (US06720351-20040413-C00013.png)
EC (1) ECSP034925A (US06720351-20040413-C00013.png)
EE (1) EE05452B1 (US06720351-20040413-C00013.png)
ES (1) ES2307799T3 (US06720351-20040413-C00013.png)
GE (2) GEP20053720B (US06720351-20040413-C00013.png)
GT (1) GT200200136A (US06720351-20040413-C00013.png)
HK (2) HK1064369A1 (US06720351-20040413-C00013.png)
HR (1) HRP20031051B1 (US06720351-20040413-C00013.png)
HU (1) HU229551B1 (US06720351-20040413-C00013.png)
IL (1) IL158516A0 (US06720351-20040413-C00013.png)
IS (1) IS2603B (US06720351-20040413-C00013.png)
MA (1) MA27045A1 (US06720351-20040413-C00013.png)
MX (1) MXPA03011707A (US06720351-20040413-C00013.png)
MY (1) MY129328A (US06720351-20040413-C00013.png)
NO (1) NO326700B1 (US06720351-20040413-C00013.png)
NZ (1) NZ528752A (US06720351-20040413-C00013.png)
OA (1) OA12626A (US06720351-20040413-C00013.png)
PA (1) PA8549301A1 (US06720351-20040413-C00013.png)
PE (1) PE20030135A1 (US06720351-20040413-C00013.png)
PL (1) PL367680A1 (US06720351-20040413-C00013.png)
PT (1) PT1404653E (US06720351-20040413-C00013.png)
RS (1) RS50712B (US06720351-20040413-C00013.png)
SI (1) SI1404653T1 (US06720351-20040413-C00013.png)
SK (1) SK287806B6 (US06720351-20040413-C00013.png)
TN (1) TNSN03146A1 (US06720351-20040413-C00013.png)
TW (2) TWI313264B (US06720351-20040413-C00013.png)
UA (1) UA75660C2 (US06720351-20040413-C00013.png)
UY (1) UY27360A1 (US06720351-20040413-C00013.png)
WO (1) WO2003002533A1 (US06720351-20040413-C00013.png)
ZA (1) ZA200307818B (US06720351-20040413-C00013.png)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
KR100575944B1 (ko) * 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
WO2003057175A2 (en) * 2002-01-02 2003-07-17 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
AU2004212004B2 (en) * 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
AU2004249124A1 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US7598046B2 (en) 2003-06-19 2009-10-06 Laboratories Serono Sa Use of prion conversion modulating agents
JP2007511500A (ja) * 2003-11-14 2007-05-10 ファイザー・プロダクツ・インク 肥満治療のためのmtp阻害剤の固体非晶性分散体
EP1716137A1 (en) 2004-02-04 2006-11-02 Pfizer Products Incorporated Substituted quinoline compounds
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7417066B2 (en) 2005-06-08 2008-08-26 Schering Ag Inhibitors of soluble adenylate cyclase
DE102005027274A1 (de) * 2005-06-08 2006-12-14 Schering Ag Inhibitoren der löslichen Adenylatzyklase
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1948163A2 (en) * 2005-10-18 2008-07-30 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1973575B1 (en) 2005-12-22 2019-07-24 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
SI3091011T1 (en) 2006-04-07 2018-06-29 Vertex Pharmaceuticals Incorporated Modulators of ATP conveyor belt conveyors
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ, インコーポレイテッド Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
EP2118206B9 (en) 2007-02-09 2018-08-29 Visen Medical, Inc. Polycyclo dyes and use thereof
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
WO2009090210A2 (en) * 2008-01-16 2009-07-23 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
JP5711151B2 (ja) * 2010-01-06 2015-04-30 武田薬品工業株式会社 インドール誘導体
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3381899B1 (en) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
EP2665708A4 (en) * 2011-01-20 2014-07-09 Univ Colorado Regents MODULATORS OF THE TLR3 / DSRNA COMPLEX AND APPLICATIONS THEREOF
CN102108070B (zh) * 2011-01-26 2013-05-22 上海优贝德生物医药有限公司 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
US9624172B2 (en) 2014-02-17 2017-04-18 Hetero Research Foundation Polymorphs of lomitapide and its salts
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
BR112016023422A8 (pt) 2014-04-15 2021-07-20 Vertex Pharma dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
RS61150B1 (sr) 2016-12-09 2020-12-31 Vertex Pharma Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutske kompozicije, postupci lečenja, i postupak za dobijanje modulatora
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN112608271A (zh) * 2020-11-26 2021-04-06 安润医药科技(苏州)有限公司 酰胺衍生物及其在制备ep4受体拮抗剂中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US4397855A (en) 1981-06-26 1983-08-09 Warner-Lambert Company 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US5416009A (en) 1991-01-23 1995-05-16 The United States Of America Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis
ZA931601B (en) 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
PT832069E (pt) 1995-06-07 2003-06-30 Pfizer Derivados de tetrahidro-isoquinolin-6-il amida do acido bifenilo-2-carboxilico sua preparacao e sua utilizacao como inibidores de proteina de transferencia de triglicerido microsomal e/ou da secrecao de apolipoproteina b (apo b)
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DE69529849T2 (de) 1995-06-07 2003-09-04 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
EP0879120A1 (de) 1996-02-02 1998-11-25 Merritt, Mark W. Vorrichtung zum bearbeiten eines stranges aus plastischem material
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU716151B2 (en) 1996-11-27 2000-02-17 Pfizer Inc. Apo B-secretion/MTP inhibitory amides
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6337344B1 (en) 1997-12-24 2002-01-08 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors or factor Xa
KR20010025074A (ko) 1998-05-22 2001-03-26 니뽄 신야쿠 가부시키가이샤 Mtp 활성 저하 조성물
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US6855715B1 (en) * 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19945594A1 (de) 1999-09-23 2001-03-29 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19963234A1 (de) 1999-12-27 2002-01-24 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1259484B1 (en) 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
US20020032238A1 (en) 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
DE10033337A1 (de) 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2816940A1 (fr) 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
GB0109287D0 (en) 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
KR100575944B1 (ko) * 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(mtp) 및/또는아포지방단백질 b(apo b)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
ZA200502495B (en) 2002-02-28 2005-09-20 Japan Tobacco Inc Ester compound and medicinal use thereof.

Also Published As

Publication number Publication date
SI1404653T1 (sl) 2008-12-31
DE60228447D1 (de) 2008-10-02
NO20035607D0 (no) 2003-12-16
CA2451474C (en) 2009-06-16
KR100575919B1 (ko) 2006-05-02
EA007008B1 (ru) 2006-06-30
IS2603B (is) 2010-04-15
AP1649A (en) 2006-08-07
BG108487A (bg) 2005-04-30
CR7151A (es) 2004-02-23
EP1404653B1 (en) 2008-08-20
HRP20031051B1 (en) 2012-01-31
IL158516A0 (en) 2004-05-12
SK16102003A3 (sk) 2004-08-03
CA2451474A1 (en) 2003-01-09
US6720351B2 (en) 2004-04-13
PT1404653E (pt) 2008-09-23
US7482368B2 (en) 2009-01-27
CN1522246B (zh) 2010-04-21
US6949572B2 (en) 2005-09-27
AR036158A1 (es) 2004-08-18
US20050080108A1 (en) 2005-04-14
EE200400040A (et) 2004-06-15
NZ528752A (en) 2006-06-30
BR0210616A (pt) 2004-09-28
US20030187053A1 (en) 2003-10-02
CY1108407T1 (el) 2014-02-12
WO2003002533A1 (en) 2003-01-09
KR20060006107A (ko) 2006-01-18
IS6988A (is) 2003-10-09
US20060194772A1 (en) 2006-08-31
HK1064369A1 (en) 2005-01-28
GEP20053720B (en) 2006-01-10
PA8549301A1 (es) 2003-02-14
GEP20063720B (en) 2006-01-10
HK1096665A1 (en) 2007-06-08
HUP0400348A2 (hu) 2004-12-28
RS100403A (en) 2007-02-05
EP1404653A1 (en) 2004-04-07
MXPA03011707A (es) 2004-03-19
JP4139325B2 (ja) 2008-08-27
CN1880304A (zh) 2006-12-20
TNSN03146A1 (fr) 2005-12-23
AP2002002567A0 (en) 2002-06-30
JP2004537541A (ja) 2004-12-16
EA200301310A1 (ru) 2004-06-24
OA12626A (en) 2006-06-13
US7348355B2 (en) 2008-03-25
ATE405548T1 (de) 2008-09-15
US6979692B2 (en) 2005-12-27
HUP0400348A3 (en) 2011-07-28
MY129328A (en) 2007-03-30
UA75660C2 (en) 2006-05-15
US20050288335A1 (en) 2005-12-29
PE20030135A1 (es) 2003-03-03
CZ20033558A3 (cs) 2004-04-14
ES2307799T3 (es) 2008-12-01
ECSP034925A (es) 2004-02-26
CN1522246A (zh) 2004-08-18
HRP20031051A2 (en) 2005-08-31
PL367680A1 (en) 2005-03-07
KR20040013006A (ko) 2004-02-11
US20040087625A1 (en) 2004-05-06
UY27360A1 (es) 2003-01-31
CN1880304B (zh) 2010-11-24
DK1404653T3 (da) 2008-10-06
NO326700B1 (no) 2009-02-02
TW200628447A (en) 2006-08-16
MA27045A1 (fr) 2004-12-20
AU2002307839B2 (en) 2006-03-16
HU229551B1 (hu) 2014-01-28
ZA200307818B (en) 2004-10-07
GT200200136A (es) 2003-05-15
RS50712B (sr) 2010-06-30
TWI313264B (en) 2009-08-11
EE05452B1 (et) 2011-08-15
KR100575944B1 (ko) 2006-05-02

Similar Documents

Publication Publication Date Title
SK287806B6 (sk) Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
AU2002307839A1 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
NL1028192C2 (nl) Gesubstitueerde chinolineverbindingen.
AU2005224129B2 (en) Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
JPH08119923A (ja) グリシンアミド誘導体、その製法およびそれを含有する医薬
EP1578725A1 (en) Microsomal triglyceride transfer protein inhibitors
WO2004056775A1 (en) Microsomal triglyceride transfer protein inhibitors
AU2007343063A1 (en) 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
JP5628937B2 (ja) 5−ht6受容体リガンドとしてのスルホン化合物

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: PAH USA 15 LLC, NEW YORK, NY, US

Free format text: FORMER OWNER: PFIZER PRODUCTS INC., GROTON, CT, US

Effective date: 20121001

TC4A Change of owner's name

Owner name: ZOETIS P LLC, FLORHAM PARK, NEW JERSEY, US

Effective date: 20130724

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150524